By Maiara Marx Luz Fiusa, Marco Antonio Carvalho-Filho1, Joyce M Annichino-Bizzacchi and Erich V De Paula
Published in BMC Med. 2015 May 6;13(1):105. doi: 10.1186/s12916-015-0327-2. (open access)
BACKGROUND: Coagulation and innate immunity have been linked together for at least 450 million years of evolution. Sepsis, one of the world’s leading causes of death, is probably the condition in which this evolutionary link is more evident. However, the biological and the clinical relevance of this association have only recently gained the attention of the scientific community.
DISCUSSION: During sepsis, (more…)
Stephen C. Stearns, the Edward P Bass Professor of Ecology and Evolutionary Biology at Yale University
Ruslan Medzhitov, the David W. Wallace Professor of Immunobiology at Yale University School of Medicine and an Investigator with the Howard Hughes Medical Institute
This textbook is intended for use in undergraduate, graduate, medical school, and continuing medical education (CME) courses, aimed at both students and professionals in medicine and public health. It discusses the evolution of patients and diseases, defenses and pathogens, cancer as an evolutionary process, vulnerabilities created by the evolution of reproduction, mismatch to modern environments, the evolution of mental disorders, and conflicts between the good of the individual patient and the welfare of the population (see brief Table of Contents below and detailed Table of Contents via the following link). This book’s professional illustrations and summaries of chapters and sections make its messages readily accessible.
To view Chapter 5 and the detailed Table of Contents visit the ‘Sample Content’ link:
Travel support for this meeting is available from Tri-CEM, the new evolutionary medicine Center at Duke University directed by Charlie Nunn.
The abstract deadline is NOW!
July 30 – August 1, 2015
Institute of Evolutionary Medicine (IEM)
University of Zurich, Switzerland
This international conference will bring together distinguished keynote speakers as well as experts from different research areas (including medicine, anthropology, molecular/evolutionary biology, paleopathology, archaeology, epidemiology, and other fields) to debate the evolutionary origins of diseases and on how the knowledge of the past informs the present and the future. Furthermore, the specific implications of interdisciplinary research in the understanding and management of human health issues will be addressed.
All abstracts for mini-symposia, oral and poster presentations will be reviewed by a scientific committee and – when accepted – published in the Journal of Evolutionary Medicine. The best student abstract will be awarded a prize by the scientific committee. Students can also apply for a competitive travel grant.
This is the sister meeting to the recent meeting of the International Society for Evolution, Medicine and Public Health at Arizona State University’s Center for Evolution and Medicine
Divergent and convergent evolution in metastases suggest treatment strategies based on specific metastatic sites
By Jessica J. Cunningham, Joel S. Brown, Thomas L. Vincent, and Robert A. Gatenby
In Evol Med Public Health published 20 March 2015, 10.1093/emph/eov006 (open access)
Abstract: Cancer cells, although maximally fit at their primary site, typically have lower fitness on the adaptive landscapes offered by the metastatic sites due to organ-specific variations in mesenchymal properties and signaling pathways. Clinically evident metastases will exhibit time-dependent divergence from the phenotypic mean of the primary population as the tumor cells evolve and adapt to their new circumstances. In contrast, tumors from different primary sites evolving on identical metastatic adaptive landscapes exhibit phenotypic convergence so that, for example, metastases in the liver from different primary tumors will evolve toward similar adaptive phenotypes. The combination of evolutionary divergence from the primary cancer phenotype and convergence towards similar adaptive strategies in the same tissue cause significant variations in treatment responses particularly for highly targeted therapies. This suggest that optimal therapies for disseminated cancer must take into account the site(s) of metastatic growth as well as the primary organ.